Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 4,084 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Steroid treatment Clear all
Completed Phase 4 Interventional Results available

Subcutaneous vs. Intramuscular Testosterone

NCT03091348
View directory record Official record
Conditions
Testosterone Deficiency, Hypogonadism, Male
Interventions
Testosterone
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis

NCT02367833
View directory record Official record
Conditions
Bone; Disorder, Development and Growth
Interventions
Combined Oral Contraceptive, Transdermal Contraceptive, Contraceptive Vaginal Ring
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 13, 2026, 7:02 PM EDT
Recruiting Phase 2 Interventional

Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant

NCT06315309
View directory record Official record
Conditions
GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
ATG Combined with Tacrolimus and Mini Methotrexate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

NCT00005578
View directory record Official record
Conditions
Cardiac Toxicity, Lymphoma
Interventions
bleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2008
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 13, 2026, 7:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

NCT03165734
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Physician's Choice medications
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
42
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 13, 2026, 7:02 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo

NCT02191748
View directory record Official record
Conditions
Vitiligo
Interventions
Needling, Triamcinolone
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

NCT01783548
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP Nasal Aerosol, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
63
States / cities
Hot Springs, Arkansas • Costa Mesa, California • Downey, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 13, 2026, 7:02 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Does Steroid Plus CO2 Laser Improve Lichen Sclerosus Symptoms Compared to Steroids Alone?

NCT05243563
View directory record Official record
Conditions
Vulvar Lichen Sclerosus
Interventions
MonaLisa Touch, Topical steroid
Device · Drug
Lead sponsor
University of South Alabama
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 13, 2026, 7:02 PM EDT
Not listed Phase 2 Interventional

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

NCT01466114
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions
estriol, Placebo, Norethindrone, Progestin Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 13, 2026, 7:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT04691804
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions
Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone
Drug
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

NCT00227591
View directory record Official record
Conditions
Essential Thrombocythemia, Polycythemia Vera, Primary Myelofibrosis
Interventions
lenalidomide, prednisone, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

NCT01493310
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, placebo, nab-paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 1 Interventional

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383
View directory record Official record
Conditions
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Interventions
Ixazomib (MLN9708), Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes

NCT03174288
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exercise, Spironolactone
Other · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 4 Interventional

Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

NCT00574470
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
daclizumab, infliximab
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 13, 2026, 7:02 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fractionated 1927-nm Non Ablative Thulium Laser in Treating Post Inflammatory Hyperpigmentation

NCT06149780
View directory record Official record
Conditions
Healthy
Interventions
Patients treated with laser
Device
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis

NCT01115582
View directory record Official record
Conditions
Inborn Errors of Bile Acid Synthesis
Interventions
Cholic acid
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 2 Interventional

Sequential High-Dose Chemotherapy and Stem Cell Transplantation in Treating Patients With Chemotherapy-Sensitive Metastatic Breast Cancer

NCT00002680
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cyclophosphamide, megestrol acetate, melphalan, tamoxifen citrate, thiotepa, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 1 Interventional Results available

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

NCT04447027
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
Interventions
Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone, EKG, Bone Marrow Aspiration/Biopsy, MRI, Lumbar Puncture, TTE
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 13, 2026, 7:02 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

NCT02911142
View directory record Official record
Conditions
Primary Effusion Lymphoma, B-Cell Neoplasm
Interventions
Lenalidomide, Rituximab, Prednisone, Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, CT of neck, chest, abdomen and pelvis, 18FDG-PET scan, MRI Brain, Bone marrow biopsy, EKG, Echocardiogram, Ultrasound, Bronchoscopy, Endoscopy, CXR: PA/lat/decub
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 7:02 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PREGNANT Short Cervix Trial

NCT00615550
View directory record Official record
Conditions
Preterm Delivery, Short Cervix, Short Uterine Cervical Length
Interventions
progesterone, placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
465 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 13, 2026, 7:02 PM EDT
Not listed Phase 4 Interventional

A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart

NCT00690950
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Dutasteride
Drug
Lead sponsor
Urologic Consultants of Southeastern PA
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 13, 2026, 7:02 PM EDT
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 13, 2026, 7:02 PM EDT